McKesson's ( MCK) first-quarter earnings rose 8% from a year ago, benefiting from balanced revenue growth among its three main business lines. The health care services company earned $184 million, or 60 cents a share, in the quarter, up from $171 million, or 55 cents a share, a year ago. The latest quarter included pretax charges of $26 million related to an investment and a segment restructuring. It also had $8 million in share-based compensation costs. Revenue rose 13% from a year ago to $23.6 billion, from $21 billion a year ago. The company reiterated full-year earnings guidance of $2.55 to $2.70 a share; analysts are looking for $2.63 a share. McKesson's pharmaceuticals-solutions unit saw revenue rise 12% in the quarter and gross profit rise to $644 million from $594 million in the first quarter of last year. The gain reflected "strong revenue growth, new agreements with pharmaceutical manufacturers, an increased mix of higher-margin generic products, stabilization of sell margin to customers" plus an inventory credit. Medical-surgical solutions revenue rose 18% in the first quarter, while operating profit fell 24% to $22 million. "Last quarter, we announced our intent to focus on the higher-growth, higher-margin alternate site sector of the medical-surgical market," McKesson said."We were pleased to have quickly found an appropriate buyer for our non-strategic acute care business, one that we expect continue to deliver the high levels of service and quality that have distinguished our operations." In provider technologies, sales rose 19%, while operating profit in the quarter rose 13% to $35 million.